Loading clinical trials...
Loading clinical trials...
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
Daratumumab
Lenalidomide
+1 more
Locations
145
United States
Little Rock, Arkansas, United States
Gainesville, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
Start Date
July 23, 2014
Primary Completion Date
March 7, 2016
Completion Date
November 21, 2024
Last Updated
May 1, 2025
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions